We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Blue Light-Filtering Intraocular Insert Increases Macular Pigment

By HospiMedica International staff writers
Posted on 19 Nov 2009
A new study shows that implantation of blue light-filtering intraocular lens (IOL) at the time of cataract surgery may afford protection against the development and progression of age-related macular degeneration (AMD). More...


Researchers at the Waterford Institute of Technology (WIT; Ireland) conducted a prospective study in which 42 patients scheduled for cataract surgery were randomized to implantation with a blue light-filtering Alcon natural intraocular lens (ANIOL) or a standard acrylic IOL (control). Macular pigment optical density (MPOD) was measured by heterochromatic flicker photometry, and serum concentrations of the macular carotenoids lutein and zeaxanthin were quantified by high performance liquid chromatography, firstly prior to surgery and then at several post-procedural time points, over a one-year follow-up period.

The results showed there was a highly significant and positive correlation between all MPODs recorded one week before and after surgery in eyes with an AIOL implant and in those with ANIOL implants. Average MPOD across the retina increased significantly with time (after 3 months) in the ANIOL group, but remained stable in the AIOL group. There were no significant time or lens effects observed for serum lutein over the study period, in contrast with a significant time effect for serum zeaxanthin over the same period, but not a significant time/lens interaction. The study was published in the October 2009 issue of Investigative Ophthalmology & Visual Science.

"Blue light-filtering lenses filter and block damaging blue light from reaching the retina, which holds the potential of reducing vision loss and improving the quality of life for millions of older patients,” said lead author John Nolan, Ph.D., deputy director of the macular pigment research group at WIT. "Since prolonged exposure to blue light is harmful to the retina, increased levels of macular pigment are considered a strong surrogate marker for protection against the processes that cause age-related blindness, including AMD.”

Macular pigment (MP), which consists of the carotenoids lutein, zeaxanthin, and meso- zeaxanthin, has a maximum absorption at 460 nm and protects the retina from photo-oxidative injury. MP is thought to protect against AMD because it absorbs short-wavelength (blue) light before it reaches photoreceptors in the retina and because of its antioxidant properties.

Related Links:
Waterford Institute of Technology








Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Digital Color Doppler Ultrasound System
MS22Plus
Hemostatic Agent
HEMOBLAST Bellows
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.